Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis ...
In A Nutshell Dissolving microneedle patches embedded with microscopic bubbles deliver three acne medications simultaneously, ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...
The open-label Phase 3 trial evaluated the safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne over a 40-week period. Denifanstat is being developed by Ascletis for acne in ...
Back pain is one of the most common of all health complaints and, for nearly six million people, the pain is constant and ...
Miami, Florida / Syndication Cloud / January 23, 2026 / Trybello LLC Key Takeaways Female pattern hair loss affects about 12% ...
It's a favourite among celebrities ...
Here's how to handle those pesky bumps.
Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.
Targeted therapies have been moved forward in the treatment of both pemphigus and pemphigoid diseases, a factor behind an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results